[1] Wisplinghoff H,Bischoff T,Tallent SM,et al.Nosocomial bloodstream infections in US hospitals:analysis of 24,179 cases from a prospective nationwide surveillance study[J].Clin Infect Dis,2004,39(3):309-317.
[2] Gonzalez GM,Trevino-Rangel RJ,Palma-Nicolas JP,et al.Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico:a nationwide surveillance study[J].J Antimicrob Chemother,2013,68(12):2847-2851.
[3] Pfaller MA,Diekema DJ,Jones RN,et al.International surveillance of bloodstream infections due to Candida species:frequency of occurrence and in vitro susceptibilities to fluconazole,ravuconazole,and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program[J].J Clin Microbiol,2001,39(9):3254-3259.
[4] Xiao M,Fan X,Chen SC,et al.Antifungal susceptibilities of Candida glabrata species complex,Candida krusei,Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China:3 year national surveillance[J].J Antimicrob Chemother,2015,70(3):802-810.
[5] Alexander BD,Johnson MD,Pfeiffer CD,et al.Increasing echinocandin resistance in Candida glabrata:clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations[J].Clin Infect Dis,2013,56(12):1724-1732.
[6] Kaur R,Domergue R,Zupancic M L,et al.A yeast by any other name:Candida glabrata and its interaction with the host[J].Curr Opin Microbiol,2005,8(4):378-384.
[7] Gabaldon T,Martin T,Marcet-Houben M,et al.Comparative genomics of emerging pathogens in the Candida glabrata clade[J].BMC Genomics,2013,14:623.
[8] Pfaller MA,Diekema DJ,Gibbs DL,et al.Results from the ARTEMIS DISK Global Antifungal Surveillance Study,1997 to 2007:a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion[J].J Clin Microbiol,2010,48(4):1366-1377.
[9] Pfaller MA,Castanheira M,Messer SA,et al.Echinocandin and triazole antifungal susceptibility profiles for Candida spp.,Cryptococcus neoformans,and Aspergillus fumigatus:application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program(2009)[J].Diagn Microbiol Infect Dis,2011,69(1):45-50.
[10] Liu W,Tan J,Sun J,et al.Invasive candidiasis in intensive care units in China:in vitro antifungal susceptibility in the China-SCAN study[J].J Antimicrob Chemother,2013,69(1):162-167.
[11] Wang H,Xiao M,Chen SC,et al.In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net(CHIF-NET) Study[J].J Clin Microbiol,2012,50(12):3952-3959.
[12] Redding S W,Dahiya MC,Kirkpatrick WR,et al.Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer[J].Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2004,97(1):47-52.
[13] Luque AG,Biasoli MS,Tosello ME,et al.Oral yeast carriage in HIV-infected and non-infected populations in Rosario,Argentina[J].Mycoses,2009,52(1):53-59.
[14] Chen S C,Tong ZS,Lee OC,et al.Clinician response to Candida organisms in the urine of patients attending hospital[J].Eur J Clin Microbiol,2008,27(3):201-208.
[15] Krcmery V,Barnes AJ.Non-albicans Candida spp.causing fungaemia:pathogenicity and antifungal resistance[J].J Hosp Infect,2002,50(4):243-260.
[16] Cohen Y,Karoubi P,Adrie C,et al.Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients[J].Crit Care Med,2010,38(3):826-830.
[17] Hui M,Ho WH,Lam WH,et al.Candida glabrata fungaemia:the importance of anaerobic blood culture[J].J Med Microbiol,2009,58(Pt 3):396-397.
[18] Shin JH,Chae MJ,Song JW,et al.Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia[J].J Clin Microbiol,2007,45(8):2385-2391.
[19] Scherer S,Stevens DA.Application of DNA typing methods to epidemiology and taxonomy of Candida species[J].J Clin Microbiol,1987,25(4):675-679.
[20] Becker K,Badehorn D,Deiwick S,et al.Molecular genotyping of Candida species with special respect to Candida(Torulopsis) glabrata strains by arbitrarily primed PCR[J].J Med Microbiol,2000,49(6):575-581.
[21] Dodgson AR,Pujol C,Denning DW,et al.Multilocus sequence typing of Candida glabrata reveals geographically enriched clades[J].J Clin Microbiol,2003,41(12):5709-5717.
[22] Lin CY,Chen YC,Lo HJ,et al.Assessment of Candida glabrata strain relatedness by pulsed-field gel electrophoresis and multilocus sequence typing[J].J Clin Microbiol,2007,45(8):2452-2459.
[23] Lockhart SR,Joly S,Pujol C,et al.Development and verification of fingerprinting probes for Candida glabrata[J].Microbiology,1997,143(Pt 12):3733-3746.
[24] Enache-Angoulvant A,Bourget M,Brisse S,et al.Multilocus microsatellite markers for molecular typing of Candida glabrata:application to analysis of genetic relationships between bloodstream and digestive system isolates[J].J Clin Microbiol,2010,48(11):4028-4034.
[25] Castanheira M,Messer SA,Rhomberg PR,et al.Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012:application of new CLSI clinical breakpoints and epidemiological cutoff values[J].Mycopathologia,2014,178(1-2):1-9.
[26] Pappas PG,Kauffman CA,Andes D,et al.Clinical practice guidelines for the management of candidiasis:2009 update by the Infectious Diseases Society of America[J].Clin Infect Dis,2009,48(5):503-535.
[27] Beyda ND,John J,Kilic A,et al.FKS mutant Candida glabrata:risk factors and outcomes in patients with candidemia[J].Clin Infect Dis,2014,59(6):819-825.
[28] Pfaller MA,Castanheira M,Lockhart SR,et al.Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata[J].J Clin Microbiol,2012,50(4):1199-1203.
[29] Pfaller MA,Andes D,Arendrup MC,et al.Clinical breakpoints for voriconazole and Candida spp.revisited:review of microbiologic,molecular,pharmacodynamic,and clinical data as they pertain to the development of species-specific interpretive criteria[J].Diagn Microbiol and Infec Dis,2011,70(3):330-343.
[30] Pfaller MA,Andes D,Diekema DJ,et al.Wild-type MIC distributions,epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida:Time for harmonization of CLSI and EUCAST broth microdilution methods[J].Drug Resist Updates,2010,13(6):180-195.
[31] Lortholary O,Renaudat C,Sitbon K,et al.Worrisome trends in incidence and mortality of candidemia in intensive care units(Paris area,2002-2010)[J].Intensive Care Med,2014,40(9):1303-1312.
[32] Andes DR,Safdar N,Baddley JW,et al.Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis:a patient-level quantitative review of randomized trials[J].Clin Infect Dis,2012,54(8):1110-1122.
[33] Eschenauer GA,Carver PL,Lin SW,et al.Fluconazole versus an echinocandin for Candida glabrata fungaemia:a retrospective cohort study[J].J Antimicrob Chemother,2013,68(4):922-926.
[34] Ruhnke M,Paiva JA,Meersseman W,et al.Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients[J].Clin Microbiol Infect,2012,18(7):680-687.
[35] Klevay MJ,Horn DL,Neofytos D,et al.Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection[J].Diagn Microbiol Infect Dis,2009,64(2):152-157.
[36] Klevay MJ,Ernst EJ,Hollanbaugh J L,et al.Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection[J].Diagn Microbiol Infect Dis,2008,60(3):273-277. |